

EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Hallie Wherley on June 3, 2011.


The application has been amended as follows:

Claim 11 has been amended to read:

"A method for treatment of NF-κB-associated diseases which comprises administering to an animal an effective amount of a concatemerized NF-κB chromosomal binding site decoy which antagonizes NF-κB-mediated transcription of a gene located downstream of a NF-κB binding site, wherein the concatemerized decoy comprises two or more end-to-end repeated copies of a domain, wherein each of the domains comprises a nucleotide sequence that acts as a NF-κB binding site decoy, wherein the concatemerized decoy is delivered by a polymeric vector, wherein the polymeric vector is a polyhydroxylamidoamine selected from the group consisting of


a poly(L-tartaramidoamine) depicted by the following structural formula:

Art Unit: 1633




wherein n is 1 or greater than 1,

a poly(D-glucaramidoamine) depicted by the following structural formula:




wherein n is 1 or greater than 1,

a poly(galactaramidoamine) depicted by the following structural formula:



wherein n is 1 or greater than 1,

and a poly(D-mannaramidoamine) depicted by the following structural formula:




wherein n is 1 or greater than 1."

Claim 17 has been amended to read:


"A method of treating a NF- κ B -dependent disease selected from the group consisting of immunological disorders, septic shock, transplant rejection, radiation damage, reperfusion injuries after ischemia, arteriosclerosis and neurodegenerative diseases, comprising administering to a mammal in need of such treatment an effective amount of a concatemerized NF- κ B chromosomal binding site decoy, wherein the concatemerized decoy comprises two or more end-to-end repeated copies of a domain, each of the domains comprising a nucleotide sequence that acts as a NF- κ B binding site, wherein the concatemerized decoy is delivered by a polymeric vector, wherein the polymeric vector is a polyhydroxylamidoamine selected from the group consisting of

a poly(L-tartaramidoamine) depicted by the following structural formula:




wherein n is 1 or greater than 1,

a poly(D-glucaramidoamine) depicted by the following structural formula:




wherein n is 1 or greater than 1,

a poly(galactaramidoamine) depicted by the following structural formula:



wherein n is 1 or greater than 1,

and a poly(D-mannaramidoamine) depicted by the following structural formula:




wherein n is 1 or greater than 1."

Claim 19 has been amended to read:


"A therapeutic method comprising treating non-aortal procedural vascular trauma comprising administering to a mammal, subjected to the procedural vascular trauma, an effective protective amount of an oligonucleotide decoy, or a pharmaceutically acceptable salt thereof comprising one or more copies of a NF-~cB binding site, wherein the oligonucleotide decoy is complexed with a polymeric delivery vector, wherein the polymeric vector is a polyhydroxylamidoamine selected from the group consisting of

a poly(L-tartaramidoamine) depicted by the following structural formula:




wherein n is 1 or greater than 1,

a poly(D-glucaramidoamine) depicted by the following structural formula:




wherein n is 1 or greater than 1,

a poly(galactaramidoamine) depicted by the following structural formula:



wherein n is 1 or greater than 1,

and a poly(D-mannaramidoamine) depicted by the following structural formula:



wherein n is 1 or greater than 1."

Any inquiry concerning this communication or earlier communications from the examiner should be directed to James D. (Doug) Schultz whose telephone number is (571)272-0763. The examiner can normally be reached on 8:00-4:30 M-F.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Joseph Woitach can be reached on 571-272-0739. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/James D. (Doug) Schultz/
Primary Examiner, Art Unit 1633